Fate Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 75 U.S.-traded ETFs. FATE has around 16.3M shares in the U.S. ETF market. The largest ETF holder of FATE is the ARK Innovation ETF (ARKK), with approximately 4.64M shares. Investors may also find of interest that the ETF with the largest allocation to FATE stock is ARK Genomic Revolution ETF (ARKG), with a portfolio weight of 4.83%. On average, U.S. ETFs allocate 0.48% of FATE to their portfolios.
Additionally, FATE is a favorite stock for Vanilla and Multi-factor ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with FATE as a holding is the ProShares UltraPro Russell2000 (URTY), with a return of 167.77%.